Simcoe Capital LLC Takes Position in Progyny, Inc. $PGNY

Simcoe Capital LLC acquired a new stake in Progyny, Inc. (NASDAQ:PGNY) in the 4th quarter, Holdings Channel.com reports. The fund acquired 151,931 shares of the company’s stock, valued at approximately $3,902,000. Progyny makes up 3.7% of Simcoe Capital LLC’s portfolio, making the stock its 11th biggest position.

Several other institutional investors and hedge funds also recently made changes to their positions in PGNY. Barclays PLC increased its stake in shares of Progyny by 79.2% in the third quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock valued at $33,904,000 after buying an additional 696,447 shares during the period. Ameriprise Financial Inc. increased its stake in shares of Progyny by 37.6% in the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after buying an additional 545,431 shares during the period. CenterBook Partners LP increased its stake in shares of Progyny by 272.7% in the third quarter. CenterBook Partners LP now owns 424,393 shares of the company’s stock valued at $9,133,000 after buying an additional 310,516 shares during the period. Qube Research & Technologies Ltd increased its stake in shares of Progyny by 161.6% in the third quarter. Qube Research & Technologies Ltd now owns 457,015 shares of the company’s stock valued at $9,835,000 after buying an additional 282,322 shares during the period. Finally, Principal Financial Group Inc. increased its stake in shares of Progyny by 57.1% in the third quarter. Principal Financial Group Inc. now owns 704,267 shares of the company’s stock valued at $15,156,000 after buying an additional 256,078 shares during the period. Institutional investors and hedge funds own 94.93% of the company’s stock.

Analyst Ratings Changes

PGNY has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. set a $35.00 target price on shares of Progyny in a research report on Wednesday, January 21st. Citizens Jmp increased their target price on shares of Progyny from $30.00 to $31.00 and gave the company a “market outperform” rating in a research report on Monday. Canaccord Genuity Group decreased their target price on shares of Progyny from $26.00 to $19.00 and set a “hold” rating for the company in a research report on Wednesday, March 11th. Truist Financial increased their target price on shares of Progyny from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Monday. Finally, KeyCorp decreased their target price on shares of Progyny from $32.00 to $28.00 and set an “overweight” rating for the company in a research report on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Progyny has an average rating of “Moderate Buy” and an average target price of $28.18.

Key Headlines Impacting Progyny

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Citizens JMP raised its price target on Progyny to $31 and reiterated a market outperform rating, signaling confidence in additional upside. Progyny (NASDAQ:PGNY) Given New $31.00 Price Target at Citizens Jmp
• Positive Sentiment: Truist Financial also increased its target to $30 and maintained a buy rating, adding to the bullish analyst sentiment around the stock. Progyny (NASDAQ:PGNY) Given New $30.00 Price Target at Truist Financial
• Positive Sentiment: Progyny’s presentation at the BofA Securities Global Healthcare Conference kept the company in front of investors and may have reinforced the growth story around its women’s health and family-building platform. Progyny, Inc. (PGNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: The company also announced it would present at the BofA Health Care Conference, which is mainly a visibility event but can attract more attention from institutional investors. Progyny, Inc. to Present at BofA Securities 2026 Health Care Conference
• Neutral Sentiment: Zacks highlighted PGNY as one of three highly ranked medical stocks, which supports the stock’s relative appeal but does not represent a company-specific catalyst. 3 Highly Ranked Medical Stocks to Buy Now: DVA, GMED, PGNY
• Negative Sentiment: The short-interest update was not meaningful because reported short interest was effectively unchanged at zero, so it does not appear to add near-term support for the stock.

Progyny Stock Up 4.0%

Shares of PGNY stock opened at $23.45 on Wednesday. The company has a market cap of $1.84 billion, a price-to-earnings ratio of 30.45, a price-to-earnings-growth ratio of 1.20 and a beta of 0.91. Progyny, Inc. has a 52 week low of $16.10 and a 52 week high of $28.75. The firm has a 50 day moving average of $18.04 and a 200-day moving average of $21.77.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.26 by $0.03. The company had revenue of $328.50 million during the quarter, compared to the consensus estimate of $326.47 million. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The company’s quarterly revenue was down 26.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.17 EPS. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Analysts anticipate that Progyny, Inc. will post 1.12 earnings per share for the current year.

Insider Activity

In other news, EVP Allison Swartz sold 4,657 shares of the stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total transaction of $81,031.80. Following the transaction, the executive vice president owned 89,879 shares of the company’s stock, valued at $1,563,894.60. This represents a 4.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders have sold 7,455 shares of company stock worth $129,515. 9.90% of the stock is owned by corporate insiders.

Progyny Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.